Paper COAs in 2026: It's Not Cheaper, It's Riskier

Clinical trials increasingly depend on reliable, inspection-ready data, yet many organizations still rely on paper for clinical outcome assessments. What appears simple on the surface carries significant, and often underestimated, risk. Paper struggles to meet core ALCOA requirements, introduces variability and missingness, and obscures true patient behavior—problems well‑documented in legacy research showing major gaps between reported and actual compliance. As trial designs grow more decentralized and endpoints more patient‑centered, these vulnerabilities compound.

Electronic COA solutions are purpose‑built to resolve these issues through time stamps, audit trails, automated logic, controlled entry windows, and real‑time visibility. These capabilities don’t merely streamline workflows; they safeguard data integrity, patient safety, and regulatory confidence. They also align with modern expectations — from FDA emphasis on patient voice to participants’ daily digital habits.

In 2026, the question is no longer whether eCOA adds value. It’s whether sponsors can afford the accumulated risk of continuing with paper. Explore how shifting to electronic assessments strengthens scientific rigor, enhances participant engagement, and protects trial timelines at every stage of development